2. Search Result
Search Result
Results for "

steatosis

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

3

Biochemical Assay Reagents

22

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0341
    Scopolin

    		Sirtuin Metabolic Disease
    Scopolin is a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots . Scopolin attenuated hepatic steatosis through activation of SIRT1-mediated signaling cascades .
    Scopolin
  • HY-N8495
    4'-Hydroxyflavanone

    		Others Metabolic Disease
    4'-Hydroxyflavanone is an inhibitor of SREBP maturation and lipid synthesis. 4'-Hydroxyflavanone is a synthetic analogue of flavanone, has potential for hepatic steatosis and dyslipidemia research .
    4'-Hydroxyflavanone
  • HY-N0157
    Orotic acid
    2 Publications Verification

    6-Carboxyuracil; Vitamin B13

    		 Nucleoside Antimetabolite/Analog Endogenous Metabolite Metabolic Disease
    Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .
    Orotic acid
  • HY-N0157A
    Orotic acid zinc
    2 Publications Verification

    6-Carboxyuracil zinc; Vitamin B13 zinc

    		 Nucleoside Antimetabolite/Analog Endogenous Metabolite Metabolic Disease
    Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .
    Orotic acid zinc
  • HY-D1168
    Oil Red O
    3 Publications Verification

    		 Fluorescent Dye Metabolic Disease
    Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
    Oil Red O
  • HY-142114
    SRI-37330
    2 Publications Verification

    		 Arrestin Metabolic Disease
    SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research .
    SRI-37330
  • HY-16521
    VX-166

    		Caspase Inflammation/Immunology
    VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .
    VX-166
  • HY-N0341R
    Scopolin (Standard)

    		Sirtuin Metabolic Disease
    Scopolin (Standard) is the analytical standard of Scopolin. This product is intended for research and analytical applications. Scopolin is a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots . Scopolin attenuated hepatic steatosis through activation of SIRT1-mediated signaling cascades .
    Scopolin (Standard)
  • HY-161892
    FABP4-IN-4

    		FABP Metabolic Disease Inflammation/Immunology
    FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .
    FABP4-IN-4
  • HY-N2953
    Borapetoside E

    		Fatty Acid Synthase (FASN) Metabolic Disease
    Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .
    Borapetoside E
  • HY-151481
    FXR antagonist 1

    		FXR Metabolic Disease
    FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC50=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .
    FXR antagonist 1
  • HY-N6869
    Dehydroabietic acid

    		Antibiotic PPAR Bacterial Fungal Infection Metabolic Disease Inflammation/Immunology Cancer
    Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
    Dehydroabietic acid
  • HY-123986
    CTPI-2
    10+ Cited Publications

    		 Mitochondrial Metabolism Inflammation/Immunology Cancer
    CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .
    CTPI-2
  • HY-N6869R
    Dehydroabietic acid (Standard)

    		Antibiotic PPAR Bacterial Fungal Infection Metabolic Disease Inflammation/Immunology Cancer
    Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
    Dehydroabietic acid (Standard)
  • HY-161926
    YGT-31

    		PPAR Metabolic Disease
    YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .
    YGT-31
  • HY-165069
    N-Docosanoyl-D-erythro-sphingosylphosphorylcholine

    Sphingomyelin (d18:1 C22:0)

    		 Others Others
    N-Docosanoyl-D-erythro-sphingosylphosphorylcholine (Sphingomyelin (d18:1 C22:0)) is a compound that appears in the plasma sphingolipid profile after chronic hepatitis C virus infection. The level of this substance in plasma is associated with hepatic steatosis and may be an independent factor of hepatic steatosis.
    N-Docosanoyl-D-erythro-sphingosylphosphorylcholine
  • HY-W588256
    12-Tridecenoic acid

    		Endogenous Metabolite Acetyl-CoA Carboxylase Infection
    12-Tridecenoic acid is a metabolite of intestinal flora, which can promote the expression of acetyl-CoA carboxylase α (ACC) and inhibit the expression of carnitine palmitoyltransferase 1A (CPT1A), thereby aggravating hepatic steatosis. 12-Tridecenoic acid aggravates hepatic steatosis by affecting the ACC-CPT1A axis .
    12-Tridecenoic acid
  • HY-N8144
    Niga-ichigoside F1

    		Others Cardiovascular Disease
    Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .
    Niga-ichigoside F1
  • HY-W505108
    2,3-Dihydroxypropyl pentadecanoate

    		Drug Metabolite Metabolic Disease
    2,3-Dihydroxypropyl pentadecanoate is a monoacylglycerol that is found in wheat bran extracts. 2,3-Dihydroxypropyl pentadecanoate levels are increased in a HepaRG cell-based model of hepatic steatosis induced by BSA-conjugated palmitate .
    2,3-Dihydroxypropyl pentadecanoate
  • HY-163531
    GPR41 modulator 2

    		Others Metabolic Disease
    GPR41 modulator 2 (Compound 10bx) exhibits agonistic activity for G protein-coupled receptor (GPR41) .
    GPR41 modulator 2
  • HY-N1419
    Vaccarin

    		AMPK Metabolic Disease
    Vaccarin is an active flavonoid glycoside associated with various biological functions. Vaccarin significantly promote wound healing and endothelial cells and fibroblasts proliferation in the wound site. Vaccarin ameliorates insulin resistance and steatosis by activating the AMPK signaling pathway .
    Vaccarin
  • HY-172105
    Anti-NASH agent 2

    		PPAR Metabolic Disease Inflammation/Immunology
    Anti-NASH agent 2 (compound 21) is an inhibitor of de novo adipogenesis activity and α-SMA gene expression. Anti-NASH agent 2 improves hepatic steatosis, edema, inflammatory infiltrates, and liver fibrosis in NASH mouse models .
    Anti-NASH agent 2
  • HY-141623
    SRI-37330 hydrochloride
    2 Publications Verification

    		 Arrestin Metabolic Disease
    SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research .
    SRI-37330 hydrochloride
  • HY-138626
    ACH-000143

    		Melatonin Receptor Metabolic Disease
    ACH-000143 is a potent and orally active melatonin receptor agonist, with EC50 values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively .
    ACH-000143
  • HY-N1478
    Gardenoside
    1 Publications Verification

    		 P2X Receptor Neurological Disease
    Gardenoside is a natural compound found in Gardenia fruits, with hepatoprotective properties. Gardenoside suppresses the pain of chronic constriction injury by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis .
    Gardenoside
  • HY-N0830B
    Palmitic acid sodium
    Maximum Cited Publications
    51 Publications Verification

    		 Biochemical Assay Reagents HSP Endogenous Metabolite Cancer
    Palmitic acid sodium is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid sodium can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells. Palmitic acid sodium is used to establish a cell steatosis model .
    Palmitic acid sodium
  • HY-N0830
    Palmitic acid
    Maximum Cited Publications
    51 Publications Verification

    		 HSP Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells. Palmitic acid is used to establish a cell steatosis model .
    Palmitic acid
  • HY-N1419R
    Vaccarin (Standard)

    		AMPK Metabolic Disease
    Vaccarin (Standard) is the analytical standard of Vaccarin. This product is intended for research and analytical applications. Vaccarin is an active flavonoid glycoside associated with various biological functions. Vaccarin significantly promote wound healing and endothelial cells and fibroblasts proliferation in the wound site. Vaccarin ameliorates insulin resistance and steatosis by activating the AMPK signaling pathway .
    Vaccarin (Standard)
  • HY-N0830A
    Palmitic acid calcium

    		HSP Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease
    Palmitic acid calcium is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells. Palmitic acid calcium is used to establish a cell steatosis model .
    Palmitic acid calcium
  • HY-112812
    SCD1 inhibitor-1

    		Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    SCD1 inhibitor-1 (Compound 48) is an orally active and liver-selective inhibitor of stearoyl-CoA desaturase 1 (SCD1) with an IC50 of 8.8 nM for recombinant human SCD1 enzyme. SCD1 inhibitor-1 can be used in the study of diseases such as diabetes, hepatic steatosis and obesity .
    SCD1 inhibitor-1
  • HY-143614
    THR-β agonist 3

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
    THR-β agonist 3
  • HY-143613
    THR-β agonist 2

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
    THR-β agonist 2
  • HY-151932
    FXR agonist 3

    		FXR Inflammation/Immunology
    FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .
    FXR agonist 3
  • HY-N0261
    Aurantio-obtusin
    1 Publications Verification

    		 TNF Receptor COX Cardiovascular Disease Inflammation/Immunology
    Aurantio-obtusin is a anthraquinone compound that can be extracted from cassia seed. Aurantio-obtusin has the effects of decreasing blood pressure, decreasing blood lipids and anti-inflammatory.Aurantio-obtusin is an orally active vasodilator. Aurantio-obtusin ameliorates hepatic steatosis through AMPK/ autophagy- and AMPK/TFEB mediated inhibition of lipid accumulation .
    Aurantio-obtusin
  • HY-142917
    THR-β agonist 4

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
    THR-β agonist 4
  • HY-151959
    FXR agonist 4

    		FXR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
    FXR agonist 4
  • HY-158127
    FABP1-IN-1
    1 Publications Verification

    		 FABP Metabolic Disease Inflammation/Immunology
    FABP1-IN-1 (44) is a selective FABP1 inhibitor, with an IC50 of 4.46 μM. FABP1-IN-1 (44) can be used for the research of NASH .
    FABP1-IN-1
  • HY-104026B
    L-Kynurenine sulfate

    		Endogenous Metabolite Aryl Hydrocarbon Receptor Inflammation/Immunology
    L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
    L-Kynurenine sulfate
  • HY-N0157C
    Orotic acid potassium
    2 Publications Verification

    6-Carboxyuracil potassium; Vitamin B13 potassium

    		 Endogenous Metabolite DNA/RNA Synthesis Metabolic Disease
    Orotic acid potassium (Vitamin B13 potassium) is a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. Orotic acid potassium stimulates the growth of animals, plants and microorganisms, participates in carbohydrate metabolism, and is necessary for the growth and life activities of organisms. Orotic acid potassium is a measurement indicator in routine newborn screening for urea cycle abnormalities. Orotic acid potassium can cause hepatic steatosis and hepatomegaly in rats .
    Orotic acid potassium
  • HY-104026BS
    L-Kynurenine-13C10 sulfate

    		Aryl Hydrocarbon Receptor Endogenous Metabolite Inflammation/Immunology
    L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
    L-Kynurenine-13C10 sulfate
  • HY-169792
    HPG1860

    		FXR Aminotransferases (Transaminases) Metabolic Disease Inflammation/Immunology
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .
    HPG1860
  • HY-104026CS
    L-Kynurenine-13C10 sulfate hemihydrate

    		Aryl Hydrocarbon Receptor Endogenous Metabolite Inflammation/Immunology
    L-Kynurenine- 13C10 (sulfate hemihydrate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate hemihydrate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
    L-Kynurenine-13C10 sulfate hemihydrate
  • HY-N0157R
    Orotic acid (Standard)

    6-Carboxyuracil (Standard); Vitamin B13 (Standard)

    		 Nucleoside Antimetabolite/Analog Endogenous Metabolite Metabolic Disease
    Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .
    Orotic acid (Standard)
  • HY-120657
    9-PAHSA

    		Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
    9-PAHSA
  • HY-N0261R
    Aurantio-obtusin (Standard)

    		TNF Receptor COX Cardiovascular Disease Inflammation/Immunology
    Aurantio-obtusin (Standard) is the analytical standard of Aurantio-obtusin. This product is intended for research and analytical applications. Aurantio-obtusin is a anthraquinone compound that can be extracted from cassia seed. Aurantio-obtusin has the effects of decreasing blood pressure, decreasing blood lipids and anti-inflammatory.Aurantio-obtusin is an orally active vasodilator. Aurantio-obtusin ameliorates hepatic steatosis through AMPK/ autophagy-and AMPK/TFEB mediated inhibition of lipid accumulation .
    Aurantio-obtusin (Standard)
  • HY-N0157S1
    Orotic acid-13C,15N2 monohydrate

    6-Carboxyuracil-13C,15N2 monohydrate; Vitamin B13-13C,15N2 monohydrate

    		 Nucleoside Antimetabolite/Analog Endogenous Metabolite Metabolic Disease
    Orotic acid- 13C, 15N2 (monohydrate) is the 13C and 15N labeled Orotic acid[1]. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[2][3][4].
    Orotic acid-13C,15N2 monohydrate
  • HY-W127408
    Tripalmitolein

    		Biochemical Assay Reagents Endogenous Metabolite Others
    1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.
    Tripalmitolein
  • HY-N1462
    Atractyloside potassium salt
    4 Publications Verification

    		 Chloride Channel Autophagy mTOR AMPK Cardiovascular Disease Metabolic Disease Cancer
    Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity .
    Atractyloside potassium salt
  • HY-N8495R
    4'-Hydroxyflavanone (Standard)

    		Others Metabolic Disease
    4'-Hydroxyflavanone (Standard)
  • HY-N1462R
    Atractyloside (potassium salt) (Standard)

    		Chloride Channel Autophagy mTOR AMPK Cardiovascular Disease Metabolic Disease Cancer
    Atractyloside (potassium salt) (Standard) is the analytical standard of Atractyloside (potassium salt). This product is intended for use in research and analytical applications. Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity .
    Atractyloside (potassium salt) (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: